Roblox, CommScope, and Neurocrine Biosciences Experience Surge in Options Trading

Today, notable options trading activity has emerged among Russell 3000 index companies, particularly for Roblox Corp (Symbol: RBLX). So far, a total of 29,087 contracts have changed hands, which is about 2.9 million underlying shares. This represents 44.2% of RBLX’s average daily trading volume of 6.6 million shares over the past month. The $63 strike call option expiring on January 10, 2025, generated significant interest with 3,394 contracts traded today, equating to approximately 339,400 underlying shares. Below is RBLX’s trading history for the past twelve months, with the $63 strike indicated in orange:

In parallel, CommScope Holding Co Inc (Symbol: COMM) reported robust options trading with a total of 17,459 contracts, which translates to around 1.7 million underlying shares. This figure is about 44.1% of COMM’s average daily trading volume of 4 million shares over the previous month. The $5 strike put option expiring on May 16, 2025, saw particularly significant movement, with 15,011 contracts traded so far today, representing approximately 1.5 million shares. Below is a chart outlining COMM’s trading history over the past year, highlighting the $5 strike:

Neurocrine Biosciences, Inc. (Symbol: NBIX) also witnessed active options trading, with 4,245 contracts traded, accounting for about 424,500 underlying shares—approximately 43.6% of NBIX’s average daily trading volume of 972,665 shares during the past month. The $145 strike call option set to expire on January 17, 2025, generated heightened interest with 2,147 contracts exchanged today, translating to roughly 214,700 underlying shares. Below is NBIX’s trading history for the twelve months, with the $145 strike highlighted:

For detailed information about available expiration dates for RBLX, COMM, or NBIX options, please visit StockOptionsChannel.com.

Today’s Most Active Call & Put Options of the S&P 500 »

Also see:

• Next Earnings Date
• PAYX Stock Predictions
• ET Videos

The views and opinions expressed herein are solely those of the author and do not necessarily reflect those of Nasdaq, Inc.